Showing results (1481-1490 of 5,686) with videos related to
Sort By:
Pageof 569
Drug Design, Development and Therapy|March 2, 2016
Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis via the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagyJingjing Li, Kan Chen, Sainan Li, et al.Drug Design, Development and Therapy|March 2, 2016
The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature reviewXiaoyu Wu, Guannan Wu, Xuequan Yao, et al.Drug Design, Development and Therapy|March 2, 2016
A network pharmacology approach to discover active compounds and action mechanisms of San-Cao Granule for treatment of liver fibrosisShizhang Wei, Ming Niu, Jian Wang, et al.Drug Design, Development and Therapy|April 5, 2016
Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokineticsPeng Ji, Tong Yu, Ying Liu, et al.Drug Design, Development and Therapy|February 19, 2016
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisV Di Lernia, F BardazziDrug Design, Development and Therapy|February 20, 2016
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's ratsLu Song, Zhanzhao Zhang, Rongguo Hu, et al.Drug Design, Development and Therapy|February 20, 2016
Establishment of a novel therapeutic vector targeting the trigeminal ganglion in ratsKun Xu, Shi-Yin Pan, Jin-Xin Song, et al.Drug Design, Development and Therapy|July 18, 2015
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry diseaseLubor Goláň, Ozlem Goker-Alpan, Myrl Holida, et al.Drug Design, Development and Therapy|July 18, 2015
Reverse phase protein arrays in signaling pathways: a data integration perspectiveChad J Creighton, Shixia HuangDrug Design, Development and Therapy|July 18, 2015
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranTimothy S Leung, Ernest H LawPageof 569